SEC Filings

Form 10-K
KINDRED BIOSCIENCES, INC. filed this Form 10-K on 03/06/2019
Document Outline
Entire Document (5652 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - TABLE OF CONTENTS
Page 4 - CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 5 - PART I.
Page 6 - Clinical Data
Page 7 - Product Candidates
Page 8 - KIND-011
Page 9 - Management Team
Page 10 - Product Selection and Development
Page 11 - Business Strategy
Page 12 - Continue to focus on the development of our pipeline
Page 13 - Commercialize our equine products with our own direct sales force in the United States and with dist
Page 14 - Pet Therapeutics Market Dynamics
Page 15 - Products in Development
Page 16 - Other Product Candidates
Page 17 - KIND-509
Page 18 - Manufacturing
Page 19 - Intellectual Property
Page 20 - Requirements for Approval of Veterinary Pharmaceuticals for Pets
Page 21 - Chemistry, Manufacturing and Controls ("CMC")
Page 22 - Regulatory Process at the EMA
Page 23 - Other Regulatory Considerations
Page 24 - Investing in our common stock involves a high degree of risk. You should carefully consider the risk
Page 25 - We are substantially dependent on the success of Mirataz as well as product candidates in our pipeli
Page 26 - Most of our current and future small molecule product candidates are or will be based on generic hum
Page 27 - If our product candidates are approved, they may face significant competition and may be unable to c
Page 28 - The development of our biologic product candidates is dependent upon relatively novel technologies a
Page 29 - Our Protocol Concurrences with the FDA for our pivotal studies do not guarantee marketing approval i
Page 30 - Development of pet therapeutics is inherently expensive, time-consuming and uncertain, and any delay
Page 31 - Even if we obtain regulatory approval of one or more of our current or future product candidates, th
Page 32 - If we fail to retain current members of our senior management, or to attract and keep additional key
Page 33 - The commercialization of Mirataz or any of our product candidates could be adversely affected if we
Page 34 - We currently have a small commercial organization. If we are unable to expand sales capabilities on
Page 35 - Consolidation of our customers could negatively affect the pricing of our products.
Page 36 - Mirataz and, if approved, our product candidates may be marketed in the United States only in the ta
Page 37 - Risks Related to Intellectual Property
Page 38 - If our efforts to protect the proprietary nature of the intellectual property related to Mirataz or
Page 39 - We may be involved in lawsuits to protect or enforce any patents issued to us, which could be expens
Page 40 - Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our abi
Page 41 - We have one registered US trademark for our current product candidate KINDLET, as well as one regist
Page 42 - Any of our current or future approved products may cause or contribute to adverse medical events tha
Page 43 - Certain of our product candidates currently in development may be classified as controlled substance
Page 44 - Risks Related to Our Common Stock
Page 45 - If securities or industry analysts do not publish research or reports about our company, or if they
Page 46 - Because we are no longer an "emerging growth company," as defined in the JOBS Act, we must incur add
Page 47 - Provisions in our charter documents and under Delaware law could discourage a takeover that stockhol
Page 48 - Our stockholder rights agreement could discourage a takeover that stockholders may consider favorabl
Page 49 - ITEM 4.MINE SAFETY DISCLOSURES.
Page 50 - PART II
Page 51 - Recent Sales of Securities
Page 52 - Repurchase of Shares
Page 53 - Statement of Operations
Page 54 - RESULTS OF OPERATIONS
Page 55 - N/A
Page 56 - N/A
Page 57 - Financial Overview
Page 58 - Interest and Other Income, Net
Page 59 - Product Returns
Page 60 - Stock-Based Compensation
Page 61 - Results of Operations
Page 62 - Concentrations of credit risk
Page 63 - Selling, General and Administrative Expense
Page 64 - Restructuring Costs
Page 65 - Cash Flows
Page 66 - Net cash provided by (used in) investing activities
Page 67 - Contractual Obligations
Page 68 - Interest Rate Fluctuation Risk
Page 69 - Evaluation of Disclosure Controls and Procedures
Page 70 - PART III
Page 71 - PART IV
Page 72 - EXHIBIT INDEX
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - SIGNATURES
Page 77 - Index to Consolidated Financial Statements
Page 78 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 79 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 80 - N/A
Page 81 - Kindred Biosciences, Inc.
Page 82 - Kindred Biosciences, Inc.
Page 83 - Kindred Biosciences, Inc.
Page 84 - Kindred Biosciences, Inc.
Page 85 - Kindred Biosciences, Inc
Page 86 - Kindred Biosciences, Inc.
Page 87 - Kindred Biosciences, Inc.
Page 88 - Kindred Biosciences, Inc.
Page 89 - Kindred Biosciences, Inc.
Page 90 - Kindred Biosciences, Inc.
Page 91 - Kindred Biosciences, Inc.
Page 92 - Kindred Biosciences, Inc.
Page 93 - Kindred Biosciences, Inc.
Page 94 - Kindred Biosciences, Inc.
Page 95 - Kindred Biosciences, Inc.
Page 96 - Kindred Biosciences, Inc.
Page 97 - Kindred Biosciences, Inc.
Page 98 - Kindred Biosciences, Inc.
Page 99 - Kindred Biosciences, Inc.
Page 100 - Kindred Biosciences, Inc.
Page 101 - Kindred Biosciences, Inc.
Page 102 - Kindred Biosciences, Inc.
Page 103 - Kindred Biosciences, Inc.
Page 104 - Kindred Biosciences, Inc.
Page 105 - Kindred Biosciences, Inc.
Page 106 - Kindred Biosciences, Inc.
Page 107 - Kindred Biosciences, Inc.
Page 108 - Kindred Biosciences, Inc.
Page 109 - Kindred Biosciences, Inc.
Page 110 - Kindred Biosciences, Inc.
Subdocument 2 - EX-21.1 - EXHIBIT 21.1
Page 1 - N/A
Subdocument 3 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Subdocument 4 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 5 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 6 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer